Turn Therapeutics to present atopic dermatitis update

Turn Therapeutics will present detailed atopic dermatitis clinical program data at a Stifel virtual forum, with the event webcast and archived on its investor website.

Rhea-AI Filing Summary

Turn Therapeutics Inc. (TTRX) reported that it will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum under a Regulation FD disclosure.

On September 23, 2026, Chief Executive Officer Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., are scheduled to present an update on the atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy and emerging findings in distinct patient populations. The presentation will be available via live webcast and replay for approximately six months on the company’s investor relations website.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Forum presentation date: September 23, 2026 Forum presentation time: 1:30 PM Webcast replay period: Approximately six months

3 metrics

Forum presentation date September 23, 2026 Date of Turn Therapeutics’ presentation at the Stifel 2026 Virtual Immunology and Inflammation Forum

Forum presentation time 1:30 PM Scheduled time of the company’s presentation at the Stifel virtual forum

Webcast replay period Approximately six months Length of time the presentation replay will be available on the Turn Therapeutics website

Key Terms

atopic dermatitis, pruritus-focused stage 2 enrichment strategy, EASI, IGA, +1 more

5 terms

atopic dermatitis medical

"The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

pruritus-focused stage 2 enrichment strategy medical

"including its pruritus-focused stage 2 enrichment strategy and emerging findings"

EASI medical

"a clinically important cohort characterized by lower EASI scores despite high"

Eczema Area and Severity Index (EASI) is a standardized clinical score used to measure the extent and intensity of atopic dermatitis (eczema) on a patient’s body, combining how much skin is affected and how severe symptoms like redness and thickness are. For investors, EASI matters because it is often a primary endpoint in dermatology drug trials: larger or faster improvements in EASI can increase the chance of regulatory approval and commercial success, much like a clear test score can boost confidence in a new product.

IGA medical

"lower EASI scores despite high investigator-assessed disease severity (IGA)"

IgA (immunoglobulin A) is an antibody that acts like a first-line security guard on the body's surfaces—such as the gut, respiratory tract and eyes—helping block infections and clear harmful substances. For investors, IgA matters because it is a target and a biomarker in diagnostics and drug development for infections, autoimmune conditions and some kidney diseases; changes in IgA levels can influence clinical trial outcomes, regulatory decisions and market demand for treatments and tests.

clinical-stage biotechnology company medical

"Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Turn Therapeutics Inc. (TTRX) announce in this Form 8-K?

Turn Therapeutics Inc. disclosed that it issued a press release announcing its participation in the Stifel 2026 Virtual Immunology and Inflammation Forum, where executives will present details on its atopic dermatitis clinical program via a live webcast and subsequent replay.

When will TTRX present at the Stifel 2026 Virtual Immunology and Inflammation Forum?

Turn Therapeutics is scheduled to present on September 23, 2026, at 1:30 PM during the Stifel 2026 Virtual Immunology and Inflammation Forum, focusing on its atopic dermatitis clinical program and related patient population findings.

What clinical program will Turn Therapeutics (TTRX) highlight in the presentation?

The company will highlight its atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy and emerging findings in patients with moderate-severe baseline pruritus and those with lower EASI scores but high investigator-assessed disease severity (IGA).

Will the Turn Therapeutics (TTRX) Stifel forum presentation be available online?

Yes. A live webcast of the presentation will be accessible via the Investors section of the Turn Therapeutics website, and a replay will be available there for approximately six months following the presentation.

Who from Turn Therapeutics (TTRX) will speak at the Stifel 2026 forum?

The presentation will be delivered by Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, providing a detailed look at the company’s atopic dermatitis clinical program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 08:11 AM Accepted by SEC EDGAR 09/10/2026 - 08:10 AM Learn about SEC filing dates

false 0002023016 0002023016 2026-09-10 2026-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42875		32-0456090
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

250 N. Westlake Blvd., Westlake Village, California		91362
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (818) 564-4011

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		TTRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 10, 2026, Turn Therapeutics Inc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated September 10, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TURN THERAPEUTICS INC.
Date: September 10, 2026
	By:	/s/ Bradley Burnam
	Name:	Bradley Burnam
	Title:	Chief Executive Officer

2

Exhibit 99.1

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Westlake Village, Calif. – September 10, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:

Date: September 23, 2026
Time: 1:30 PM ET

The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well as a clinically important cohort characterized by lower EASI scores despite high investigator-assessed disease severity (IGA).

A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/events. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.

About Turn Therapeutics

Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies designed to act directly at the site of disease. The Company’s lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for onychomycosis. Turn’s research focuses on the intersection of microbial activity, local immune signaling and chronic inflammation.

For more information, visit www.turntherapeutics.com.

Investor Relations / Media Contact

Sasha Damouni

Damouni Group LLC

sasha@turntherapeutics.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 PRESS RELEASE, DATED SEPTEMBER 10, 2026 4.3 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB